Compare STRO & REAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRO | REAL |
|---|---|---|
| Founded | 2003 | 2011 |
| Country | United States | United States |
| Employees | 131 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 338.9M | 1.9B |
| IPO Year | N/A | 2019 |
| Metric | STRO | REAL |
|---|---|---|
| Price | $24.42 | $8.82 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $22.29 | $17.00 |
| AVG Volume (30 Days) | 139.5K | ★ 3.5M |
| Earning Date | 03-23-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.55 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $692,845,000.00 |
| Revenue This Year | N/A | $14.30 |
| Revenue Next Year | $13.45 | $10.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 15.38 |
| 52 Week Low | $0.52 | $4.61 |
| 52 Week High | $27.96 | $17.39 |
| Indicator | STRO | REAL |
|---|---|---|
| Relative Strength Index (RSI) | 63.74 | 31.78 |
| Support Level | $0.76 | $7.21 |
| Resistance Level | $27.96 | $11.17 |
| Average True Range (ATR) | 2.43 | 0.53 |
| MACD | -0.30 | -0.05 |
| Stochastic Oscillator | 60.55 | 8.39 |
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
The RealReal is the largest pure-play luxury resale platform in the US, generating $1.8 billion in 2024 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 36% of net merchandise value in 2024, which excludes returns, cancellations, and first-party sales.